Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
|Articles|June 27, 2022
The Building Blocks of Decentralized Clinical Trials
Author(s)Medable
A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.
Related to this article
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Who Answers for Your Data? Building a Life Sciences Data Mesh
4
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
5